Cosmetics Europe LRSS Programme
|
|
- Morgan Dorsey
- 6 years ago
- Views:
Transcription
1 Cosmetics Europe LRSS Programme Rob Taalman
2 Objectives of CE Research To deliver tools & strategies for animal-free safety assessment Accurate Robust Efficient ultimately accepted by regulators
3 Our Systematic Rationale Exposure Exposure upon use Local effects Skin, eye irritation Penetration, Metabolism, Excretion Skin penetration, metabolism Bioavailability at systemic target site Systemic Effects Sensitization, genotoxicity (Sub-) chronic toxicity Safety Assessment
4 Current LRSS Situation LRSS = triple package ❶Develop non-animal methods & testing strategies to be used for safety assessment of cosmetics ingredients / chemicals ❷Show that safety assessment thus probabilistic & realistic assessment is possible on a broad spectrum of effects / likelihoods including systemic toxicity ❸Advocate for the regulatory acceptance of data generated with such alternative methods
5 Current LRSS Situation 5 task forces 1. Eye Irritation 2. Genotoxicity 3. Skin tolerance 4. Bioavailability & Metabolism / ToxicoKinetics (TK) 5. Mode of Action / ToxicoDynamics (TD) Well advanced combination of alternative methods towards reg. accep. Systemic toxicity based on non-animal methods only Big challenge Discussed for decades Many attempts to achieve this But so far not accepted
6 AAT Strategic Roadmap 2013 Skin Irritation Eye Irritation Genotoxicity Acute Toxicity 2020 Sensitization Systemic Toxicity 2016 Eye Irritation Genotoxicity Skin sensitization Exposure / ADME Systemic Toxicity
7 Eye Irritation
8 Eye Irritation Strategy 2012
9 Eye Irritation Today ( ) X
10 Genotoxicity
11 Evolution of Genotoxicity Requirements SCCS Notes of guidance in vitro battery: Ames MLA MN Ames MN 3D Comet 3D MN High Sensitivity Low false positive ratio Reduced costs Skin assays accepted followup option Successful Validation is prerequisite for maintaining We personally status quo! care
12 Genotoxicity Strategy supported by SCCS and OECD Drastically less false positives by 2-assay strategy Evaluation of tier 2 assays progressing Finalize validation of 3D skin model assays in 2016 Support validation of Hen s Egg micronucleus test as viable option to follow-up on orally exposed ingredients Goal to have 2 assays/strategy approved by scientific/regulatory community in 2017/18
13 Skin Sensitization
14 Skin Sensitization - OECD Adverse Outcome Pathways - Chemistry Penetration Metabolism Immunology Chemical reactivity Protein modification Cellular response Organ response In vivo response Integrated assessment Expert systems in silico tools
15 Skin Sensitization - OECD Adverse Outcome Pathways - Chemistry Penetration Metabolism Immunology Chemical reactivity Protein modification Cellular response Organ response In vivo response Three in vitro assays validated DPRA, KeratinoSens, hclat Additional 13 assays evaluated Six methods prioritized (incl. DPRA, KeratinoSens and hclat) Promising prediction models being assessed e.g. Support Vector Machines, Bayesian models
16 Skin Sensitization - OECD Adverse Outcome Pathways - Chemistry Penetration Metabolism Immunology Chemical reactivity Protein modification Cellular response Organ response In vivo response Researching assays
17 Overview Skin Sensitization Achievements Assays developed / validated / evaluated Clear roadmap Challenges ( ) Potency determination Testing strategy finalization Regulatory acceptance Status 6 OECD-submitted data interpretation procedures (DIP s) evaluated Assay optimization & data integration Characterize & expand applicability domain
18 Systemic Toxicity
19 Back to the basics
20 Paradigm shift QIVI VE *adapted from P. Price (US EPA), Using in vitro data in quantitative risk assessments
21 Strategy Systemic Toxicity Exposure - Toxicokinetics - Systemic exposure predictions Hazard Identification - Toxicodynamics - Mechanistic predictions Fusion Concentration response data Modelling - Case Studies - Safety Assessment Combined evaluation & extrapolation
22 Systemic Toxicity - Status SEURAT-1 final event 4 Dec SEURAT-1 level 3 case studies Proof-of-concept, TTC, Read-across framework, ab initio Differential planning vs. public programs
23 Toxicokinetics / ADME - Objectives Internal exposure For read-across and ab initio risk assessments Enable internal TTCs Guidance for in vitro assays (concentrations, target organs)
24 Toxicokinetics / ADME - Principles Fate of a chemical after exposure via different routes Topical exposure Local concentrations in different organs Metabolism Distribution Excretion Organ-specific toxicity Reactive metabolite formation or detoxification PK profile, C max, AUC
25 Toxicokinetics / ADME - Status Protein binding Solubility Partition/ diffusion coefficients Lipid binding (Physico-) chemical properties In silico models In silico models Skin penetration (non-viable skin) Bioavailability & Metabolism Metabolism in ex vivo skin Metabolism, stability in S9 50 compounds tested Q3/2016 In silico models 2017
26 Toxicokinetics / ADME - Way Forward Exposure In silico Skin Penetration Prediction Models ADME in vitro Toolbox intestinal absorption liver metabolism in vitro biokinetics plasma protein binding Static & Dynamic 3D Skin & Liver Models Internal TTC PBPK ADME Model Read across / ab initio concepts
27 Toxicodynamics - Objectives Discriminate between specific and non specific adversities and low toxicity Determine perturbed biological pathways for repeat dose toxicity Establish quantitative points of departure for use in risk assessment (linked to kinetics)
28 Toxicodynamics Building Blocks Mode of Action Ontology ( ) Bio-/ Chemoinformatics Data ( ) Toxicogenomics ( ) Toxicodynamic AssayToolbox ( ) Quantify dose which can alter biological pathway(s)
29 Toxicodynamics Building Blocks Mode of Action Ontology ( ) Bio-/ Chemoinformatics Data ( ) Toxicogenomics ( ) Toxicodynamic AssayToolbox ( )
30 Toxicodynamics Building Blocks - Mode of Action Ontology - Knowledge-based grouping of chemical features associated with repeat dose toxicity into categories, tie to a putative mode of toxicity (or not) Mode of Action Ontology Bio-/ Chemoinformatics Data ( ) ( ) Toxicogenomics ( ) Toxicodynamic AssayToolbox ( )
31 Toxicodynamics Building Blocks - Toxicogenomics - Front line screen for broad characterization of hazard Mode of Action Ontology Bio-/ Chemoinformatics Data ( ) ( ) Toxicogenomics ( ) Toxicodynamic AssayToolbox ( )
32 Toxicodynamics Building Blocks - Toxicodynamic Assay Toolbox - In vitro assays for generating toxicodynamic data Address identified gaps Source of targeting testing Mode of Action Ontology Bio-/ Chemoinformatics Data ( ) ( ) Toxicogenomics ( ) Toxicodynamic Assay Toolbox ( )
33 Toxicodynamics Building Blocks - Bio-/ Chemo-informatics Data - Informatics and integration/visualization needs of toxicity and ADME data for analysis via case studies Mode of Action Ontology Bio-/ Chemoinformatics Data ( ) ( ) Toxicogenomics ( ) Toxicodynamic AssayToolbox ( )
34 Fusion & Safety Assessment - Case Studies / Modelling / Evaluation - Case Studies as Guiding Principle Concentration response data / modelling Quantitative in vitro-in vivo extrapolation (QIVIVE)
35 Systemic Toxicity Workflow TIER 0: IDENTIFY USE SCENARIO, CHEMICAL OF CONCERN AND COLLECT EXISTING INFORMATION TIER 1: HYPOTHESIS FORMULATION TIER 2: APPLICATION 1. IDENTIFY USE SCENARIO 2. IDENTIFY MOLECULAR STRUCTURE 3. COLLECT EXISTING DATA 4. IDENTIFY ANALOGUES, SUITABILITY ASSESSMENT AND EXITING DATA 5. SYSTEMIC BIOAVAILABILITY (PARENT VS. METABOLITE(S), TARGET ORGANS, INTERNAL CONCENTRATION) 6. MOA HYPOTHESIS GENERATION (WEIGHT OF EVIDENCE BASED ON AVAILABLE TOOLS) 7A. TARGETED TESTING 7B. BIOKINETIC REFINEMENT (IN VIVO CLEARANCE, POPULATION, IN VITRO STABILITY, PARTITION) 8. POINTS OF DEPARTURE, IN VITRO IN VIVO EXTRAPOLATION, UNCERTAINTY ESTIMATION, MARGIN OF SAFETY EXIT TTC EXIT READ ACROSS EXIT INTERNAL TTC 9. FINAL RISK ASSESSMENT OR SUMMARY ON INSUFFICIENT INFORMATION APPROACH EXIT AB INITIO (Adapted from Berggren et al Publication in preparation)
36 It s all connected
37 SA Paradigm = the common matrix to TK and TD TFs There are some direct links easy to draw And some others less obvious
38
39 Conclusions Highlights since 2015 OECD acceptance of eye irritation RhT tests OECD/SCCS acceptance of genotoxicity strategy SEURAT-1 case studies SCCS: positive reception of TTC for systemic toxicity ECHA: positive reception of NAMs (as supporting evidence in read-across) Cosmetics Europe LRSS roadmap largely planned
40 AAT Means Collaboration! Regulators - OECD - ECVAM - SCCS Industry - Cosmetics (LRSS) - Pharma (IMI) - Life Science - Chemicals (LRI) - ECETOC EPA EPAA Public Sector - E.C. (Horizon 2020) - JRC - Academia, institutes Thank you!
The Long Range Science Strategy (LRSS) of Cosmetics Europe
The Long Range Science Strategy (LRSS) of Cosmetics Europe Repeated dose systemic toxicity 2016 Bas Blaauboer Aim of LRSS: Development of a strategy to determine safety of cosmetic ingredients and products
More informationNON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS. Cutting-Edge Science and Constant Innovation: The Keys to Success
NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS Cutting-Edge Science and Constant Innovation: The Keys to Success 2 NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS Cutting-Edge
More informationSEURAT-1: Why predictive safety science is important to regulatory acceptance of alternative methods
1 SEURAT-1: Why predictive safety science is important to regulatory acceptance of alternative methods Ian A Cotgreave Swedish Toxicology Sciences Research Center On behalf of all SEURAT-1 partners 10
More informationEURL ECVAM. A broader role for greater impact. Maurice Whelan. Head of Systems Toxicology Unit and EURL ECVAM
EURL ECVAM A broader role for greater impact Maurice Whelan Head of Systems Toxicology Unit and EURL ECVAM Institute for Health and Consumer Protection DG Joint Research Centre Meeting of the EP Intergroup
More informationIntegrated Approaches to Testing and Assessment (IATA) ex. Skin Sensitisation
Integrated Approaches to Testing and Assessment (IATA) ex. Skin Sensitisation João Barroso 10 th EPAA Annual Conference Brussels, 2014 Conventional Toxicology Chemical Animal model Pancreatic tumor Observe
More informationThe Role of Chemistry in Adverse Outcome Pathways. Paul Russell & Steve Gutsell Safety and Environmental Assurance Centre, Unilever April 2013
The Role of Chemistry in Adverse Outcome Pathways Paul Russell & Steve Gutsell Safety and Environmental Assurance Centre, Unilever April 2013 Contents Background Risk Assessment in FMCG industry Drivers
More informationDEVELOPMENT OF INTEGRATED APPROACHES TO TESTING AND ASSESSMENT AT OECD
DEVELOPMENT OF INTEGRATED APPROACHES TO TESTING AND ASSESSMENT AT OECD Joint Cefic LRI/Cosmetics Europe/EPAA workshop 23-24 April 2015 Promoting the regulatory use of alternative test methods The OECD
More informationNeeds and Future Perspectives of Modelling Skin Permeability and Metabolism
Needs and Future Perspectives of Modelling Skin Permeability and Metabolism Mark Cronin School of Pharmacy and Chemistry Liverpool John Moores University England E-mail: m.t.cronin@ljmu.ac.uk Reasons for
More informationEPAA 3Rs Science Award 2012
EPAA 3Rs Science Award 2012 Systematic approach to investigate outliers of the fish embryo test to increase its predictive capacity and applicability domain for acute fish toxicity and beyond Nils Klüver,
More informationMain achievements & Progress in Gianni Dal Negro, GlaxoSmithKline Industry Co-Chair EPAA Steering Committee
Main achievements & Progress in 2011 Gianni Dal Negro, GlaxoSmithKline Industry Co-Chair EPAA Steering Committee Overview of EPAA activities in 2011 Focus on Integrated Testing Strategies (annual theme)
More informationMoving Towards Version 2.0 of Toxicity Testing in the 21 st Century and Application to Regulatory Decision Making
Moving Towards Version 2.0 of Toxicity Testing in the 21 st Century and Application to Regulatory Decision Making ECHA Topical Scientific Workshop on New Approach Methodologies April 20, 2016 Rusty Thomas
More informationRisk Management under the Chemicals Management Plan
Risk Management under the Chemicals Management Plan Hazard Characterization and Tools for Health Risk Assessment under CMP Stakeholder Advisory Council meeting Health Canada PAHO Workshop Lima, Peru November
More informationDosing for Controlled Exposure (DoCE): Dosing strategies for characterising in vitro dose-responses with increased relevance for in vivo extrapolation
Dosing for Controlled Exposure (DoCE): Dosing strategies for characterising in vitro dose-responses with increased relevance for in vivo extrapolation Background Chemical safety assessments continue to
More informationTox21: Opportunities& Challenges. Richard A. Becker Ph.D., DABT American Chemistry Council
Tox21: Opportunities& Challenges Richard A. Becker Ph.D., DABT American Chemistry Council October 21, 2010 Opportunities and Challenges The manifest challenge is to develop in vitro and in silico approaches
More informationToxicity testing in the 21st Century: Challenges and Opportunities
Toxicity testing in the 21st Century: Challenges and Opportunities Alan R Boobis Imperial College London a.boobis@imperial.ac.uk 10 th CONCAWE Symposium 26 th February, 2013 Brussels, Belgium Risk assessment
More informationWorkshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017
Workshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017 Presentation Outline Should we account for kinetics in vitro and in vivo for
More informationThe WHO Framework for Combined Exposures and MOA/AOP Analysis; Implications for Euromix. Euromix Kick Off Meeting
The WHO Framework for Combined Exposures and MOA/AOP Analysis; Implications for Euromix Euromix Kick Off Meeting M.E. (Bette) Meek University of Ottawa bmeek@uottawa.ca Contents of the WHO IPCS Framework
More informationAcceptance of New Technology. Richard Phillips, ExxonMobil Petroleum & Chemical CEFIC LRI 11th Annual Workshop, 19 November 2009
Acceptance of New Technology Richard Phillips, ExxonMobil Petroleum & Chemical CEFIC LRI 11th Annual Workshop, 19 November 2009 Overview Acceptance of New Technology Within LRI Nanotechnology New Approaches
More informationProgress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies
Progress and Future Directions in Integrated Systems Toxicology Mary McBride Agilent Technologies 1 Toxicity testing tools of the late 20 th century Patchwork approach to testing dates back to the 1930
More informationSafety Assessment in the 21 st Century
Safety Assessment in the 21 st Century PCPC Legal & Regulatory Conference 6 May 2016 Donald L. Bjerke, PhD, DABT The Procter & Gamble Company Outline Common ground Safety assessment basic principles Safety
More informationCurrent State of the Science in Chemical Risk Assessment
Current State of the Science in Chemical Risk Assessment M.E. (Bette) Meek McLaughlin Centre University of Ottawa, Ottawa, Canada Email:bmeek@uottawa.ca Outline The Evolution of Regulatory Mandates & Implications
More informationFrom Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase
An Executive Summary From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase Leveraging knowledge about an API s physicochemical properties
More informationDISCOVER OUR SEGMENT REGULATORY SCIENCE
DISCOVER OUR SEGMENT REGULATORY SCIENCE Our focus In the demanding regulatory environment of the EU, expert knowledge is essential to gaining approval for substances and products. That is why the scientific
More informationILSI AGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA) PROJECT: A TIERED TESTING APPROACH. November 18, 2005
ILSI AGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA) PROJECT: A TIERED TESTING APPROACH Ann Blacker, PhD, DABT Head of Regulatory Toxicology Bayer CropScience November 18, 2005 HESI ACSA Technical Committee
More informationINDUSTRY S NEEDS FOR 21 ST CENTURY SAFETY SCIENCE & NON-ANIMAL APPROACHES: A UNILEVER PERSPECTIVE
INDUSTRY S NEEDS FOR 21 ST CENTURY SAFETY SCIENCE & NON-ANIMAL APPROACHES: A UNILEVER PERSPECTIVE JULIA FENTEM & GAVIN MAXWELL UNILEVER R&D SAFETY & ENVIRONMENTAL ASSURANCE CENTRE (SEAC) CONTEXT - 1 Our
More informationChagas Disease Drug Discovery Entering a New Era. Eric Chatelain, PhD Head of Drug Discovery
Chagas Disease Drug Discovery Entering a New Era Eric Chatelain, PhD Head of Drug Discovery ICOPA Meeting, Mexico, 12 th August 2014 Chagas Disease Effective immune responses provide control of the infection
More information2017 PROGRAM Hands-On Training
- FORMAT - - REGISTRATION FEE - 2 days training From Thursday morning to Friday evening 590 euros* without VAT Lectures Thursday morning Laboratory practices Rest of the time Training certificate can be
More informationCEFIC Long-range Research Initiative Request for Proposals (RfP)
Title and Code Number: Enhanced Screening Methods to Determine Bioaccumulation Potential of Chemicals in Air- Breathing Species LRI ECO41 Background The globally accepted model for bioaccumulation determination
More informationApplicability of the AOP for Assessing Causality of Observations in Epidemiological Studies
Applicability of the AOP for Assessing Causality of Observations in Epidemiological Studies Presented by: M.E. Meek, University of Ottawa bmeek@uottawa.ca 2 Outline Background on Adverse Outcome Pathways
More informationUse of Adverse Outcome Pathways (AOPs) to reduce uncertainty and animal use in chemical hazard and risk assessment
Use of Adverse Outcome Pathways (AOPs) to reduce uncertainty and animal use in chemical hazard and risk assessment MatTek, Inc. MatTek, Inc. Reinnervate, Inc. Molecular initiating event Intermediate Events
More informationThe Dose: Toxicokinetics for Human Health Risk Assessment
The Dose: Toxicokinetics for Human Health Risk Assessment John C. Lipscomb, PhD, DABT, ATS U.S. Environmental Protection Agency Office of Research and Development National Center for Environmental Assessment
More informationNew Approaches to Chemical Risk Assessment
New Approaches to Chemical Risk Assessment Wednesday, 11 May, 13.30-15.00 IAFP s European Symposium on Food Safety 2016, Athens, Greece New Approaches in Chemical Risk Assessment Dr Ans Punt RIKILT Wageningen
More informationCost Reduction in REACH Alternatives to Testing ChemicalWatch EXPO Berlin, April 2017 Peter Jenkinson CEHTRA
Consultancy for Environmental and Human Toxicology and Risk Assessment Science Beyond Regulatory Compliance Cost Reduction in REACH Alternatives to Testing ChemicalWatch EXPO Berlin, April 2017 Peter Jenkinson
More informationCategory approaches, Read-across, (Q)SAR
Category approaches, Read-across, (Q)SAR Technical Report No. 116 EUROPEAN CENTRE FOR ECOTOXICOLOGY AND TOXICOLOGY OF CHEMICALS Category approaches, Read-across, (Q)SAR Technical Report No. 116 Brussels,
More information06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND
Preclinical Support for Exploratory Phase I Clinical Trials Clive Joseph, DSRD Sandwich Overview Identify the most appropriate development paradigm - traditional vs alternative IND approach Confidence
More informationTHE SYSTEMATIC REVIEW OF MECHANISTIC DATA IN IRIS ASSESSMENTS
THE SYSTEMATIC REVIEW OF MECHANISTIC DATA IN IRIS ASSESSMENTS Catherine Gibbons, Ph.D. U.S. EPA The views expressed in this presentation are those of the author and do not necessarily reflect the views
More informationAn NGO Perspective on Regulatory Acceptance of Non-animal Data and Related Issues. Martin Stephens, Ph.D. The Humane Society of the United States
An NGO Perspective on Regulatory Acceptance of Non-animal Data and Related Issues Martin Stephens, Ph.D. The Humane Society of the United States Animal Use Numbers Rabbits 222,167 Guinea pigs 203,098 Hamsters
More informationPHYSIOLOGICALLY-BASED KINETIC MODELLING IN RISK ASSESSMENT REACHING A WHOLE NEW LEVEL IN REGULATORY DECISION-MAKING At a glance*
The European Commission s science and knowledge service Joint Research Centre PHYSIOLOGICALLY-BASED KINETIC MODELLING IN RISK ASSESSMENT REACHING A WHOLE NEW LEVEL IN REGULATORY DECISION-MAKING At a glance*
More informationUpdate of the WHO/IPCS Mode of Action Framework
Update of the WHO/IPCS Mode of Action Framework ECETOC/WHO/IPCS Mode of Action Workshop Vienna, February 21 st 22 nd, 2013 Presented by: M.E. (Bette) Meek University of Ottawa bmeek@uottawa.ca Outline
More informationQSAR APPLICATION TOOLBOX, v 4.1 BASIC PRACTICAL TRAINING WORKSHOP. BARCELONA, SPAIN November, 2017 AGENDA
QSAR APPLICATION TOOLBOX, v 4.1 BASIC PRACTICAL TRAINING WORKSHOP BARCELONA, SPAIN 20-21 November, 2017 AGENDA Monday, 20 November 2017 (09:00 17:00) 09:00-09:30 Registration and Toolbox loading onto computers.
More informationPathway-based Approaches to Safety Assessment: development and use
Pathway-based Approaches to Safety Assessment: development and use Molecular initiating event Intermediary steps Adverse Outcome Catherine Willett, PhD Director, Regulatory Testing Risk Assessment and
More informationHow to bring your registration dossier in compliance with REACH Tips and Hints - Part 5
How to bring your registration dossier in compliance with REACH Tips and Hints - Part 5 Read-across Niklas Andersson 12 February Read-across - Definition Read-across is a technique for predicting endpoint
More informationPharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal
Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents
More informationPERFORMANCE BASED VALIDATION APPROACHES AT OECD. Patience Browne Test Guidelines Programme, OECD SOT IVAMSS October 25, 2017
PERFORMANCE BASED VALIDATION APPROACHES AT OECD Patience Browne Test Guidelines Programme, OECD SOT IVAMSS October 25, 2017 Why is Validation such a big deal at OECD? Harmonised international testing methods
More informationS9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create
More informationValidation of the 21 st Century Toxicology Toolbox: Challenges, Opportunities, and the Way Forward
Validation of the 21 st Century Toxicology Toolbox: Challenges, Opportunities, and the Way Forward William S. Stokes 1, Judy Strickland 2, and Warren Casey 1 1 National Toxicology Program Interagency Center
More informationWorkshop Report. Abstract Summary
Experts Workshop on Read-Across Assessment Organised by ECHA with the active support from Cefic-LRI (October 3, 2012) Use of read-across for Chemical Safety Assessment under REACH Workshop Report Abstract
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationGlobal Development Challenges: Classical and Advanced Therapy Medicinal products
Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES
More informationChapter 21. Toxicity Testing
Chapter 21 Toxicity Testing Toxicity Testing There are two purposes of toxicity testing. There is a quantitative effort to elucidate a dose effect relationship There is a qualitative determination of the
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL
EN EN EN EUROPEAN COMMISSION Brussels, 16.9.2010 COM(2010) 480 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL Report on the Development, Validation and Legal Acceptance of
More informationEFSA Guidance on the Submission of a. Evaluation: Toxicological data
Committed since 2002 to ensuring that Europe s food is safe EFSA Guidance on the Submission of a Dossier on Food Enzymes for Safety Evaluation: Toxicological data Prof. Karl-Heinz Engel CEF Panel member
More informationOrganisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development
Unclassified ENV/JM/MONO(2017)27 ENV/JM/MONO(2017)27 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 27-Sep-2017 English
More informationCatherine Willett, Humane Society of the United States, Humane Society International
The Use of Adverse Outcome Pathways (AOPs) to Support Chemical Safety Decisions within the Context of Integrated Approaches to Testing and Assessment (IATA) Catherine Willett, Humane Society of the United
More informationCommitted since 2002 to ensuring that Europe s food is safe. David Gott. Chair & Rapporteur - WG Guidance on Food Additives
Committed since 2002 to ensuring that Europe s food is safe Risk assessment paradigm David Gott Vice-chair chair of the ANS Panel Chair & Rapporteur - WG Guidance on Food Additives Stakeholders workshop
More informationGuidelines for application of chemical-specific adjustment factors in dose/concentration response assessment
Toxicology 181 182 (2002) 115 120 www.elsevier.com/locate/toxicol Guidelines for application of chemical-specific adjustment factors in dose/concentration response assessment M.E. Meek a, *, A. Renwick
More informationTHE OECD PROGRAM ON ADVERSE OUTCOME PATHWAYS (AOP)
THE OECD PROGRAM ON ADVERSE OUTCOME PATHWAYS (AOP) WC-9 Satellite meeting AOP 101 24 August 2014 Anne Gourmelon Principal Administrator OECD Test Guidelines Programme Environmental, Health and Safety Division
More informationThree recently approved in vivo genotoxicity test guidelines
Three recently approved in vivo genotoxicity test guidelines (Revised in February 2018) a. Title of the test guideline (year of original adoption, year of update) In Vitro Mammalian Cell Gene Mutation
More informationAlternative Testverfahren und intelligente Teststrategien Position der EU-Kommission. Thomas Hartung & ECVAM Team.
Alternative Testverfahren und intelligente Teststrategien Position der EU-Kommission Thomas Hartung & ECVAM Team Institute for Health and Consumer Protection (IHCP) Ispra (Va), Italy http://ecvam.jrc.it
More informationMB Expands Capabilities Adds Ames Test, MTD and Range Finding
What's New @ MB? MB Expands Capabilities - Ames, PK, MTD, Range Finding New! - PorCORA - Non-Animal Ocular Irritation/Reversibility Test Under Development - PorFocal - Low-Level Ocular Irritation Screening
More informationRevidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität
Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität PD Dr. Elke Röhrdanz Präklinik Fachgebiet Klinische Prüfung
More informationGuideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation
1 2 3 21 July 2016 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling
More informationUnited States Environmental Protection Agency (EPA) Office of Pesticide Programs (OPP): The Vision for Global Pesticide Reviews
2009/SOM2/SCSC/WKSP2/011 United States Environmental Protection Agency (EPA) Office of Pesticide Programs (OPP): The Vision for Global Pesticide Reviews Submitted by: United States Examination of Hot Issues
More informationC.3.9. Repeated Dose Dermal Toxicity: 21/28-Day Study (OECD TG 410)
C.3.9. REPEATED DOSE DERMAL TOXICITY: 21-28-DAY STUDY (OECD TG 410) 557 C.3.9. Repeated Dose Dermal Toxicity: 21/28-Day Study (OECD TG 410) Status: Assay validated by the OECD. 841. Modalities detected:
More informationKey Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety
Safeguarding public health Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety David R Jones (david.jones@mhra.gsi.gov.uk) Expert Pharmacotoxicologist, Medicines and
More informationProblem Formulation: Lessons and Tools from Practical Applications Involving Systematic Review of Mechanistic Data
Problem Formulation: Lessons and Tools from Practical Applications Involving Systematic Review of Mechanistic Data Dr. Daniele Wikoff Health Sciences Practice Director Innovative Solutions Sound Science
More informationADVERSE OUTCOME PATHWAYS: WHERE DO YOU START?
ADVERSE OUTCOME PATHWAYS: WHERE DO YOU START? Terry Schultz Presented at: Adverse Outcome Pathways 101: The How and Why of Development and Use. Phoenix, AZ 25 March 2014 THE AIM OF MY PRESENTATION is to
More informationDeputy Director General of Enterprise and Industry DG. Global Cooperation on alternatives (3Rs) to animal testing
Ref. Ares(2012)1356871-16/11/2012 SPEECH Antti PELTOMÄKI Deputy Director General of Enterprise and Industry DG Opening speech for the 8 th EPAA Annual Conference Global Cooperation on alternatives (3Rs)
More informationMode of Action and Human Relevance Framework in the context of Classification and Labelling (CLH) and regulatory assessment of biocides and pesticides
Mode of Action and Human Relevance Framework in the context of Classification and Labelling (CLH) and regulatory assessment of biocides and pesticides Workshop Proceedings Helsinki, 4 November 2014 Mode
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationCurrent Guidelines for Drug-drug Interaction Evaluation
Current Guidelines for Drug-drug Interaction Evaluation Odette A Fahmi, PhD DDI-Edge Consulting, LLC June 2018 21 ST International Conference on Drug-Drug Interactions OUTLINE Recommended DDI approaches
More informationCASE STUDYS: APPLYING ALTERNATIVE APPROACHES
CASE STUDYS: APPLYING ALTERNATIVE APPRACHES Dr. Wera Teubner, BASF Schweiz AG 12th Stakeholders` Day, April 5th, 2017 at ECHA, Helsinki, Finnland 1 Case study 1: In-vitro methods Alternative methods have
More informationNew methods: miniorgans
New methods: miniorgans C. Rovida CAAT-Europe, University of Konstanz 16 maggio 2018 Parma Summer School 2018 Emerging Risks for Food Safety and Public Perception 1981 2010 www.ecopa.eu 2012 Stakeholder
More informationNON-ANIMAL SKIN SENSITIZATION TESTING UNDER REACH
NON-ANIMAL SKIN SENSITIZATION TESTING UNDER REACH Walter Westerink, PhD Charles River Laboratories Den Bosch 10 October 2017 EVERY STEP OF THE WAY EVERY STEP OF THE WAY Introduction Direct Peptide Reactivity
More informationUsage of (eco)toxicological data for bridging data gaps between and grouping of nanoforms of the same substance. Elements to consider
Usage of (eco)toxicological data for bridging data gaps between and grouping of nanoforms of the same substance Elements to consider Nanomaterials based solutions have a lot to offer for a wide range of
More informationAn ASEAN guidance document for evaluating the safety of botanical. [Version ] Botanical Safety Assessment.
ASEAN Cosmetic Scientific Body Botanical Safety Assessment Guidance Document [Version 2014-01] An ASEAN guidance document for evaluating the safety of botanical An ASEAN Guidance document for evaluating
More informationEvolving approaches to AOP development: observations from MOA frameworks to systems biology
Evolving approaches to AOP development: observations from MOA frameworks to systems biology Molecular ini'a'ng event Intermediary steps Adverse Outcome Catherine WilleI, PhD Director, Regulatory Tes'ng
More informationTechnical Notes for Guidance. on the assessment of technical equivalence of substances regulated under Directive 98/8/EC
Technical Notes for Guidance on the assessment of technical equivalence of substances regulated under Directive 98/8/EC These Technical Notes for Guidance were adopted during the 29 th meeting of representatives
More informationPrioritizing the Toxicity Testing of Environmental Chemicals at EPA
Prioritizing the Toxicity Testing of Environmental s at EPA George Gray, Ph.D. Assistant Administrator Ranking and Prioritizing s Ranking for further testing Identify compounds of greatest concern Focus
More informationChemical Safety Assessment Under REACH
Chemical Safety Assessment Under REACH Dinant Kroese TNO knowledge for business CONTENTS 1. Registration requirements 2. Core tools under REACH 3. Chemical Safety Assessment (CSA) Human Health 4. Our experience
More informationTowards a future of scientific progress without the need for experimental animals: Global trends
Towards a future of scientific progress without the need for experimental animals: Global trends Herman B.W.M.Koëter President, Alternatives Congress Trust Towards a future of scientific progress without
More informationExtrapolation of in vitro effects to in vivo embryotoxicity Basic requirements for prediction model development. Han van de Sandt, PhD
Extrapolation of in vitro effects to in vivo embryotoxicity Basic requirements for prediction model development Han van de Sandt, PhD TNO: Netherlands Organisation for Applied Scientific Research Established
More informationValue Scale (1-5) 1 I. Final Product Profile Characteristics of the product required for patient care
In this example, the majority of the compounds was active in the xenograft model and showed "drug-like" properties from in-silico and experimental data. However, the animal studies showed moderate toxicity
More informationScientifically Robust. Expert Software. Improving efficiency and aiding regulatory submission for over 30 years
Scientifically Robust Expert Software Improving efficiency and aiding regulatory submission for over 30 years Innovation through collaboration Lhasa Limited is a not-for-profit organisation and registered
More informationROLE OF OECD AND THE TEST GUIDELINES PROGRAMME IN THE REGULATORY ACCEPTANCE OF ALTERNATIVE METHODS
ROLE OF OECD AND THE TEST GUIDELINES PROGRAMME IN THE REGULATORY ACCEPTANCE OF ALTERNATIVE METHODS Anne Gourmelon Principal Administrator OECD Test Guidelines Programme Environmental, Health and Safety
More informationValue Scale (1-5) Summary of Results
In this example, the set of compounds that were studied satisfied many of the criteria for "drug likeness". However, in this program, there were issues with potency, novelty, and metabolic stability. This
More informationApproval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D.
Approval Review of Generic Drugs Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D. Outline of Presentation Introduction Approval Review of Generic Drugs Equivalency review Conformity audit Conclusion
More informationECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie)
ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationSYSTEMATIC APPROACH TO THE SAFETY ASSESSMENT OF NATURALS FOR USE IN CONSUMER PRODUCTS
SYSTEMATIC APPROACH TO THE SAFETY ASSESSMENT OF NATURALS FOR USE IN CONSUMER PRODUCTS SIVARAM TK SAFETY & ENVIRONMENTAL ASSURANCE CENTRE, UNILEVER R&D, INDIA NATURALS Natural substances are substances
More informationOral Delivery of Drugs
Oral Delivery of Drugs 1 S E S S I O N O N E O F T I P P R O J E C T Advantages of taking oral drugs Convenient (storage, portability, premeasured dose) economical non-invasive, often safer route requires
More informationProgress in the Toxicity Testing in the 21 st Century (TT21C) Proposal
Progress in the Toxicity Testing in the 21 st Century (TT21C) Proposal AXLR8 Workshop 2011 Berlin-Dahlem, Germany May 24-26, 2011 Harvey Clewell Director, Center for Human Health Assessment The Hamner
More informationEpithelial In Vitro Testing
Epithelial In Vitro Testing BLADDER SKIN MAMMARY 2D AGING CO-CULTURE CELLS 3D AIRWAY CORNEA ORAL Standard Tests Tailored Tests Custom Tests Swiss Quality Products www.cellntec.com In Vitro Tests With a
More informationAppendix R.6-1 for nanomaterials applicable to the Guidance on QSARs and Grouping of Chemicals
G U I D A N C E Guidance on information requirements and chemical safety assessment Appendix R.6-1 for nanomaterials applicable to the Guidance on QSARs and Grouping Version 1.0 May 2017 2 Appendix for
More informationGuidance for Setting Occupational Exposure Limits: Emphasis on Data-Poor Substances
Guidance for Setting Occupational Exposure Limits: Emphasis on Data-Poor Substances ISSN-0773-8072-101 Brussels, September 2006 Copyright ECETOC AISBL European Centre for Ecotoxicology and Toxicology of
More informationHazard identification Dose-response assessment Exposure assessment Risk characterization In vivo animal experiments Endpoint assays (mortality) Epidemiological studies Environmental monitoring Extrapolation
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationIN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS
IN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS PHM017E January 2014 Robert Hunter Project Analyst ISBN: 1-56965-661-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationSupplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester
IEW-M1.1 Principles in Toxicology Number of credit points (CP): 12 Introduction to general toxicology Foundations of toxicokinetics (ADME: absorption, distribution, metabolism, and excretion) Foundations
More informationInstitute for In Vitro Sciences
Outline Introduction to the Institute for In Vitro Sciences, Inc. Pathways to In Vitro Methods Acceptance In Vitro Methods Currently Accepted at OECD Level Traditional Acceptance Paradigm Alternative Approaches
More information